These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33046573)

  • 1. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
    van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
    Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).
    Grassi T; Mariani A; Cibula D; Soliman PT; Suman VJ; Weaver AL; Pedra Nobre S; Weigelt B; Glaser GE; Cappuccio S; Abu-Rustum NR
    Int J Gynecol Cancer; 2020 Oct; 30(10):1627-1632. PubMed ID: 32699021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.
    Hochreiter A; Kelly JR; Young MR; Litkouhi B; Black JD; Stromberger C; Higgins S; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2020 Jan; 30(1):48-55. PubMed ID: 31722964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of different adjuvant radiotherapy modalities on women with early-stage intermediate- to high-risk endometrial cancer.
    Jin M; Hou X; Sun X; Zhang Y; Hu K; Zhang F
    Int J Gynecol Cancer; 2019 Oct; 29(8):1264-1270. PubMed ID: 31320487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
    Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
    Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institutional outcomes of adjuvant brachytherapy for Stage I endometrial cancer-Are outcomes consistent with randomized studies?
    Dohopolski MJ; Horne ZD; Gebhardt BJ; Glaser SM; Edwards RP; Kelley JL; Comerci JT; Olawaiye AB; Courtney-Brooks M; Berger JL; Sukumvanich P; Beriwal S
    Brachytherapy; 2018; 17(3):564-570. PubMed ID: 29426745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
    Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
    Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
    Wortman BG; Bosse T; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld H; van den Berg H; Slot A; De Winter KAJ; Verhoeven-Adema KW; Smit VTHBM; Creutzberg CL;
    Gynecol Oncol; 2018 Oct; 151(1):69-75. PubMed ID: 30078506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular-integrated risk profile: An opportunity for therapeutic de-escalation in intermediate and high-intermediate risk endometrial cancer].
    Espenel S; Pointreau Y; Genestie C; Durdux C; Haie-Meder C; Chargari C
    Cancer Radiother; 2022 Oct; 26(6-7):931-937. PubMed ID: 36031498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of surgical approach on risk of recurrence after vaginal brachytherapy in early-stage high-intermediate risk endometrial cancer.
    Philp L; Tannenbaum S; Haber H; Saini A; Laurent JS; James K; Feltmate CM; Russo AL; Growdon WB
    Gynecol Oncol; 2021 Feb; 160(2):389-395. PubMed ID: 33358198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
    Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
    Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma.
    AlHilli M; Amarnath S; Elson P; Rybicki L; Dowdy S
    Int J Gynecol Cancer; 2020 Jun; 30(6):789-796. PubMed ID: 32184268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Predictive of Receiving Adjuvant Radiotherapy in High-Intermediate-Risk Stage I Endometrial Cancer.
    McGunigal M; Pollock A; Doucette JT; Liu J; Chadha M; Kalir T; Gupta V
    Int J Gynecol Cancer; 2018 Jun; 28(5):882-889. PubMed ID: 29538253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
    RAINBO Research Consortium
    Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
    Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
    Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant radiotherapy for stage I endometrial cancer.
    Kong A; Johnson N; Cornes P; Simera I; Collingwood M; Williams C; Kitchener H
    Cochrane Database Syst Rev; 2007 Apr; (2):CD003916. PubMed ID: 17443533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; D'Amico R; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Gribaudo S; Provencher D; Hanzen C; Kruitwagen RF; Smit VTHBM; Singh N; Do V; Lissoni A; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2019 Sep; 20(9):1273-1285. PubMed ID: 31345626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant radiotherapy for stage I endometrial cancer.
    Kong A; Johnson N; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.